Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease
- PMID: 33974145
- PMCID: PMC8113300
- DOI: 10.1007/s11892-021-01390-8
Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease
Abstract
Purpose of review: Diabetic kidney disease (DKD), a leading cause of end-stage kidney disease, is the result of metabolic network alterations in the kidney. Therefore, metabolomics is an effective tool for understanding its pathophysiology, finding key biomarkers, and developing a new treatment strategy. In this review, we summarize the application of metabolomics to DKD research.
Recent findings: Alterations in renal energy metabolism including the accumulation of tricarboxylic acid cycle and glucose metabolites are observed in the early stage of DKD, and they finally lead to mitochondrial dysfunction in advanced DKD. Mitochondrial fission-fusion imbalance and dysregulated organelle crosstalk might contribute to this process. Moreover, metabolomics has identified several uremic toxins including phenyl sulfate and tryptophan derivatives as promising biomarkers that mediate DKD progression. Recent advances in metabolomics have clarified the role of dysregulated energy metabolism and uremic toxins in DKD pathophysiology. Integration of multi-omics data will provide additional information for identifying critical drivers of DKD.
Keywords: Biomarker; Diabetic kidney disease; Metabolomics; Mitochondria; Organelle crosstalk; Uremic toxin.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8113300/bin/11892_2021_1390_Fig1_HTML.gif)
Similar articles
-
Clinical metabolomics characteristics of diabetic kidney disease: A meta-analysis of 1875 cases with diabetic kidney disease and 4503 controls.Diabetes Metab Res Rev. 2024 Mar;40(3):e3789. doi: 10.1002/dmrr.3789. Diabetes Metab Res Rev. 2024. PMID: 38501707
-
Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review.Transl Res. 2024 Mar;265:71-87. doi: 10.1016/j.trsl.2023.11.002. Epub 2023 Nov 10. Transl Res. 2024. PMID: 37952771 Review.
-
Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease.Diabetes Metab J. 2022 Mar;46(2):181-197. doi: 10.4093/dmj.2021.0329. Epub 2022 Mar 24. Diabetes Metab J. 2022. PMID: 35385633 Free PMC article. Review.
-
Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease.Med Res Rev. 2022 Jul;42(4):1518-1544. doi: 10.1002/med.21883. Epub 2022 Mar 10. Med Res Rev. 2022. PMID: 35274315 Review.
-
The Mitochondria-Targeted Metabolic Tubular Injury in Diabetic Kidney Disease.Cell Physiol Biochem. 2019;52(2):156-171. doi: 10.33594/000000011. Epub 2019 Feb 28. Cell Physiol Biochem. 2019. PMID: 30816665 Clinical Trial.
Cited by
-
The AKI-to-CKD Transition: The Role of Uremic Toxins.Int J Mol Sci. 2023 Nov 10;24(22):16152. doi: 10.3390/ijms242216152. Int J Mol Sci. 2023. PMID: 38003343 Free PMC article. Review.
-
NMR-Based Metabolomics to Decipher the Molecular Mechanisms in the Action of Gut-Modulating Foods.Foods. 2022 Sep 5;11(17):2707. doi: 10.3390/foods11172707. Foods. 2022. PMID: 36076892 Free PMC article.
-
In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease.Front Physiol. 2021 Nov 30;12:779683. doi: 10.3389/fphys.2021.779683. eCollection 2021. Front Physiol. 2021. PMID: 34916961 Free PMC article.
-
The Role of Gut Microbiota and Microbiota-Related Serum Metabolites in the Progression of Diabetic Kidney Disease.Front Pharmacol. 2021 Nov 24;12:757508. doi: 10.3389/fphar.2021.757508. eCollection 2021. Front Pharmacol. 2021. PMID: 34899312 Free PMC article.
-
Chronic Kidney Disease Cohort Studies: A Guide to Metabolome Analyses.Metabolites. 2021 Jul 16;11(7):460. doi: 10.3390/metabo11070460. Metabolites. 2021. PMID: 34357354 Free PMC article. Review.
References
-
- Nichols GA, Deruaz-Luyet A, Hauske SJ, Brodovicz KG. The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes. J Diabetes Complicat. 2018;32(3):291–297. doi: 10.1016/j.jdiacomp.2017.12.003. - DOI - PubMed
-
- Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744. - DOI - PubMed
-
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials